Fondaparinux
- Generic Name
- Fondaparinux
- Brand Names
- Arixtra
- Drug Type
- Small Molecule
- Chemical Formula
- C31H53N3O49S8
- CAS Number
- 104993-28-4
- Unique Ingredient Identifier
- J177FOW5JL
- Background
Fondaparinux (Arixtra) is a synthetic anticoagulant agent consisting of five monomeric sugar units and a O-methyl group at the reducing end of the molecule. It is structurally similar to polymeric glycosaminoglycan heparin and heparan sulfate (HS) when they are cleaved into monomeric units. The monomeric sequence in heparin and HS is thought to form the high...
- Indication
Approved for: (1) prophylaxis of VTE for up to one month post surgery in patients undergoing orthopedic surgery of the lower limbs such as hip fracture, hip replacement and knee surgery; (2) prophylaxis of VTE patients undergoing abdominal surgery who are at high risk of thromboembolic complications (e.g. patients undergoing abdominal cancer surgery); (3) tr...
- Associated Conditions
- Acute Pulmonary Embolism (PE), Deep Vein Thrombosis, Non ST Segment Elevation Myocardial Infarction (NSTEMI), ST Segment Elevation Myocardial Infarction (STEMI), Unstable Angina Pectoris, Acute, superficial, symptomatic Vein Thrombosis
- Associated Therapies
- -
The Use of Fondaparinux in Preventing Thromboembolism in High Risk Trauma Patients
- Conditions
- Interventions
- First Posted Date
- 2007-09-19
- Last Posted Date
- 2013-12-24
- Lead Sponsor
- Mary Knudson, M.D.
- Target Recruit Count
- 105
- Registration Number
- NCT00531843
- Locations
- 🇺🇸
San Francisco General Hospital, San Francisco, California, United States
Safety of Fondaparinux as Routine VTE Prophylaxis in Medical ICU Patients
- First Posted Date
- 2007-06-28
- Last Posted Date
- 2022-04-11
- Lead Sponsor
- Eastern Virginia Medical School
- Target Recruit Count
- 27
- Registration Number
- NCT00493896
Pharmacokinetic Study of Fondaparinux in Outpatients With Renal Dysfunction
- First Posted Date
- 2007-06-07
- Last Posted Date
- 2014-07-29
- Lead Sponsor
- Duke University
- Registration Number
- NCT00483600
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
Fondaparinux to Prevent Thrombotic Complications and Graft Failure in Patients Undergoing Coronary Artery Bypass Graft Surgery: The Fonda CABG Study
- Conditions
- First Posted Date
- 2007-05-17
- Last Posted Date
- 2007-05-28
- Lead Sponsor
- Hamilton Health Sciences Corporation
- Target Recruit Count
- 100
- Registration Number
- NCT00474591
- Locations
- 🇨🇦
Hamilton General Hospital, Hamilton, Ontario, Canada
Investigation Into the Therapeutic Dosage of Fondaparinux Sodium, a Medication Used to Prevent Blood Clots in Morbidly Obese Volunteers
- Conditions
- First Posted Date
- 2007-02-19
- Last Posted Date
- 2008-05-16
- Lead Sponsor
- University of Pittsburgh
- Target Recruit Count
- 21
- Registration Number
- NCT00436787
- Locations
- 🇺🇸
Magee Women's Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸Shadyside Medical Building, Pittsburgh, Pennsylvania, United States
Fondaparinux as Monotherapy for DVT and/or Pulmonary Embolism
- Conditions
- First Posted Date
- 2006-12-19
- Last Posted Date
- 2009-02-04
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT00413504
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Pilot Dose Finding and Pharmacokinetic Study of Fondaparinux in Children With Thrombosis
- Conditions
- First Posted Date
- 2006-12-18
- Last Posted Date
- 2015-04-15
- Lead Sponsor
- Children's Hospital Los Angeles
- Target Recruit Count
- 24
- Registration Number
- NCT00412464
- Locations
- 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸Texas Children's Hospital, Houston, Texas, United States
🇺🇸Children's Hospital of Orange County, Orange, California, United States
Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-09-28
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 44
- Registration Number
- NCT00381888
- Locations
- 🇺🇸
Crozer-Chester Medical Center, Upland, Pennsylvania, United States
🇺🇸Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
Arixtra PE Study- Outpatient Management of Stable Acute Pulmonary Embolism: Once Daily Subcutaneous Fondaparinux
- First Posted Date
- 2006-09-19
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- The Cleveland Clinic
- Registration Number
- NCT00378027
- Locations
- 🇺🇸
Cleveland Clinic 9500 Euclid Ave., Cleveland, Ohio, United States
Is Using Fondaparinux (Blood Thinner) to Treat Lung Clot Cheaper Than Traditional Therapy
- Conditions
- First Posted Date
- 2006-09-15
- Last Posted Date
- 2013-05-30
- Lead Sponsor
- University of Minnesota
- Registration Number
- NCT00377091
- Locations
- 🇺🇸
St. Mary's Medical Center, Duluth, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.